Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status

C Lunetta, A Lizio, L Tremolizzo, Massimiliano Ruscica, C Macchi, N Riva, P Weydt, E Corradi, Paolo Magni, V Sansone

Research output: Contribution to journalArticle

Abstract

Introduction: The progression of amyotrophic lateral sclerosis (ALS) leads to a decline of the nutritional status that represents an independent prognostic factor for survival. Recent studies recognize the muscle tissue as an endocrine organ able to release several molecules, called myokines. Among them, irisin seems to be involved in the regulation of metabolism, body weight and development and function of the nervous system. Objectives: (1) To evaluate irisin serum levels in patients with ALS, with comparison to healthy subjects; (2) to assess the possible association of circulating irisin levels of ALS patients with the metabolic status, clinical and biochemical features. Methods: We performed an observational, cross-sectional study in 50 ALS patients and 32 age- and sex-comparable healthy controls. Patients underwent to a complete set of neurological, pulmonary and nutritional evaluations. Serum irisin concentration was measured by enzyme immunoassay. According to indirect calorimetry, ALS patients were divided into a normo-metabolic patient group (n = 24) and a hyper-metabolic patient group (n = 26). Results: ALS patients showed significantly higher serum irisin levels compared to healthy subjects (51.0 ± 37.8 vs 13.1 ± 2.2 ng/mL, p <0.0001). Hyper-metabolic ALS patients displayed higher serum irisin levels compared to normo-metabolic ALS patients and healthy controls (p <0.0009 and p <0.0001, respectively). Serum irisin levels showed significant association with the ALSFRS-R (β=-1.18, p = 0.042), Forced Vital Capacity (β = − 0.64, p = 0.013), Fat Mass (β=-1.44, p = 0.034), pCO2 arterial blood levels (β = 2.67, p = 0.003), HCO3− arterial blood levels (β = 5.44, p = 0.001) and Free Fat Mass (β = 1.07, p = 0.025) adjusted for sex, age and metabolic status. Conclusions: ALS patients with impaired metabolic status showed higher serum irisin levels compared to normo-metabolic ALS patients and healthy subjects. Irisin levels were also negatively correlated with the extent of functional and respiratory impairment, due to as yet unknown causes, being more elevated in patients with greater disability. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
Original languageEnglish
Pages (from-to)3001-3008
Number of pages8
JournalJournal of Neurology
Volume265
Issue number12
DOIs
Publication statusPublished - 2018

Fingerprint

Amyotrophic Lateral Sclerosis
Serum
Healthy Volunteers
Fats
Indirect Calorimetry
Vital Capacity
Nutritional Status
Immunoenzyme Techniques
Nervous System
Germany
Cross-Sectional Studies
Body Weight

Cite this

Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. / Lunetta, C; Lizio, A; Tremolizzo, L; Ruscica, Massimiliano; Macchi, C; Riva, N; Weydt, P; Corradi, E; Magni, Paolo; Sansone, V.

In: Journal of Neurology, Vol. 265, No. 12, 2018, p. 3001-3008.

Research output: Contribution to journalArticle

Lunetta, C, Lizio, A, Tremolizzo, L, Ruscica, M, Macchi, C, Riva, N, Weydt, P, Corradi, E, Magni, P & Sansone, V 2018, 'Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status', Journal of Neurology, vol. 265, no. 12, pp. 3001-3008. https://doi.org/10.1007/s00415-018-9093-3
Lunetta, C ; Lizio, A ; Tremolizzo, L ; Ruscica, Massimiliano ; Macchi, C ; Riva, N ; Weydt, P ; Corradi, E ; Magni, Paolo ; Sansone, V. / Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. In: Journal of Neurology. 2018 ; Vol. 265, No. 12. pp. 3001-3008.
@article{703f6e6e01ba42beb6dbe12e67527378,
title = "Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status",
abstract = "Introduction: The progression of amyotrophic lateral sclerosis (ALS) leads to a decline of the nutritional status that represents an independent prognostic factor for survival. Recent studies recognize the muscle tissue as an endocrine organ able to release several molecules, called myokines. Among them, irisin seems to be involved in the regulation of metabolism, body weight and development and function of the nervous system. Objectives: (1) To evaluate irisin serum levels in patients with ALS, with comparison to healthy subjects; (2) to assess the possible association of circulating irisin levels of ALS patients with the metabolic status, clinical and biochemical features. Methods: We performed an observational, cross-sectional study in 50 ALS patients and 32 age- and sex-comparable healthy controls. Patients underwent to a complete set of neurological, pulmonary and nutritional evaluations. Serum irisin concentration was measured by enzyme immunoassay. According to indirect calorimetry, ALS patients were divided into a normo-metabolic patient group (n = 24) and a hyper-metabolic patient group (n = 26). Results: ALS patients showed significantly higher serum irisin levels compared to healthy subjects (51.0 ± 37.8 vs 13.1 ± 2.2 ng/mL, p <0.0001). Hyper-metabolic ALS patients displayed higher serum irisin levels compared to normo-metabolic ALS patients and healthy controls (p <0.0009 and p <0.0001, respectively). Serum irisin levels showed significant association with the ALSFRS-R (β=-1.18, p = 0.042), Forced Vital Capacity (β = − 0.64, p = 0.013), Fat Mass (β=-1.44, p = 0.034), pCO2 arterial blood levels (β = 2.67, p = 0.003), HCO3− arterial blood levels (β = 5.44, p = 0.001) and Free Fat Mass (β = 1.07, p = 0.025) adjusted for sex, age and metabolic status. Conclusions: ALS patients with impaired metabolic status showed higher serum irisin levels compared to normo-metabolic ALS patients and healthy subjects. Irisin levels were also negatively correlated with the extent of functional and respiratory impairment, due to as yet unknown causes, being more elevated in patients with greater disability. {\circledC} 2018, Springer-Verlag GmbH Germany, part of Springer Nature.",
author = "C Lunetta and A Lizio and L Tremolizzo and Massimiliano Ruscica and C Macchi and N Riva and P Weydt and E Corradi and Paolo Magni and V Sansone",
year = "2018",
doi = "10.1007/s00415-018-9093-3",
language = "English",
volume = "265",
pages = "3001--3008",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "12",

}

TY - JOUR

T1 - Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status

AU - Lunetta, C

AU - Lizio, A

AU - Tremolizzo, L

AU - Ruscica, Massimiliano

AU - Macchi, C

AU - Riva, N

AU - Weydt, P

AU - Corradi, E

AU - Magni, Paolo

AU - Sansone, V

PY - 2018

Y1 - 2018

N2 - Introduction: The progression of amyotrophic lateral sclerosis (ALS) leads to a decline of the nutritional status that represents an independent prognostic factor for survival. Recent studies recognize the muscle tissue as an endocrine organ able to release several molecules, called myokines. Among them, irisin seems to be involved in the regulation of metabolism, body weight and development and function of the nervous system. Objectives: (1) To evaluate irisin serum levels in patients with ALS, with comparison to healthy subjects; (2) to assess the possible association of circulating irisin levels of ALS patients with the metabolic status, clinical and biochemical features. Methods: We performed an observational, cross-sectional study in 50 ALS patients and 32 age- and sex-comparable healthy controls. Patients underwent to a complete set of neurological, pulmonary and nutritional evaluations. Serum irisin concentration was measured by enzyme immunoassay. According to indirect calorimetry, ALS patients were divided into a normo-metabolic patient group (n = 24) and a hyper-metabolic patient group (n = 26). Results: ALS patients showed significantly higher serum irisin levels compared to healthy subjects (51.0 ± 37.8 vs 13.1 ± 2.2 ng/mL, p <0.0001). Hyper-metabolic ALS patients displayed higher serum irisin levels compared to normo-metabolic ALS patients and healthy controls (p <0.0009 and p <0.0001, respectively). Serum irisin levels showed significant association with the ALSFRS-R (β=-1.18, p = 0.042), Forced Vital Capacity (β = − 0.64, p = 0.013), Fat Mass (β=-1.44, p = 0.034), pCO2 arterial blood levels (β = 2.67, p = 0.003), HCO3− arterial blood levels (β = 5.44, p = 0.001) and Free Fat Mass (β = 1.07, p = 0.025) adjusted for sex, age and metabolic status. Conclusions: ALS patients with impaired metabolic status showed higher serum irisin levels compared to normo-metabolic ALS patients and healthy subjects. Irisin levels were also negatively correlated with the extent of functional and respiratory impairment, due to as yet unknown causes, being more elevated in patients with greater disability. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

AB - Introduction: The progression of amyotrophic lateral sclerosis (ALS) leads to a decline of the nutritional status that represents an independent prognostic factor for survival. Recent studies recognize the muscle tissue as an endocrine organ able to release several molecules, called myokines. Among them, irisin seems to be involved in the regulation of metabolism, body weight and development and function of the nervous system. Objectives: (1) To evaluate irisin serum levels in patients with ALS, with comparison to healthy subjects; (2) to assess the possible association of circulating irisin levels of ALS patients with the metabolic status, clinical and biochemical features. Methods: We performed an observational, cross-sectional study in 50 ALS patients and 32 age- and sex-comparable healthy controls. Patients underwent to a complete set of neurological, pulmonary and nutritional evaluations. Serum irisin concentration was measured by enzyme immunoassay. According to indirect calorimetry, ALS patients were divided into a normo-metabolic patient group (n = 24) and a hyper-metabolic patient group (n = 26). Results: ALS patients showed significantly higher serum irisin levels compared to healthy subjects (51.0 ± 37.8 vs 13.1 ± 2.2 ng/mL, p <0.0001). Hyper-metabolic ALS patients displayed higher serum irisin levels compared to normo-metabolic ALS patients and healthy controls (p <0.0009 and p <0.0001, respectively). Serum irisin levels showed significant association with the ALSFRS-R (β=-1.18, p = 0.042), Forced Vital Capacity (β = − 0.64, p = 0.013), Fat Mass (β=-1.44, p = 0.034), pCO2 arterial blood levels (β = 2.67, p = 0.003), HCO3− arterial blood levels (β = 5.44, p = 0.001) and Free Fat Mass (β = 1.07, p = 0.025) adjusted for sex, age and metabolic status. Conclusions: ALS patients with impaired metabolic status showed higher serum irisin levels compared to normo-metabolic ALS patients and healthy subjects. Irisin levels were also negatively correlated with the extent of functional and respiratory impairment, due to as yet unknown causes, being more elevated in patients with greater disability. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

U2 - 10.1007/s00415-018-9093-3

DO - 10.1007/s00415-018-9093-3

M3 - Article

VL - 265

SP - 3001

EP - 3008

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 12

ER -